{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=valsartan+placebo", "query": { "intervention": "valsartan placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=valsartan+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T12:22:05.075Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03686657", "title": "Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Type 2 Diabetes", "High Blood Pressure", "Arthritis", "Obesity" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Val, Cel and Met XR Low", "type": "DRUG" }, { "name": "Val, Cel and Met XR High", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ARKAY Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2026-12-10", "completion_date": "2031-01-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 1, "location_summary": "Albany, New York", "locations": [ { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03686657" }, { "nct_id": "NCT00446511", "title": "Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Valsartan", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "placebo matched to enalapril", "type": "DRUG" }, { "name": "placebo matched to valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 250, "start_date": "2007-06", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2011-07-12", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00446511" }, { "nct_id": "NCT02884206", "title": "Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Heart Failure (CHF)" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "Placebo of LCZ696", "type": "DRUG" }, { "name": "Placebo of Valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 592, "start_date": "2016-11-23", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 52, "location_summary": "Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City West", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02884206" }, { "nct_id": "NCT00409578", "title": "Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post Acute Coronary Syndrome", "Myocardial Ischemia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Aliskiren 300 mg", "type": "DRUG" }, { "name": "Valsartan 320 mg", "type": "DRUG" }, { "name": "Aliskiren/valsartan 300/320 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1101, "start_date": "2007-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2011-04-19", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 1, "location_summary": "Investigative Site, New Jersey", "locations": [ { "city": "Investigative Site", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00409578" }, { "nct_id": "NCT00409643", "title": "Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "valsartan+amlodipine combination", "type": "DRUG" }, { "name": "valsartan", "type": "DRUG" }, { "name": "amlodipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1259, "start_date": "2004-01", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2011-11-08", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00409643" }, { "nct_id": "NCT00000620", "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Diseases", "Hypercholesterolemia", "Hypertension", "Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Coronary Disease" ], "interventions": [ { "name": "Anti-hyperglycemic Agents", "type": "DRUG" }, { "name": "Anti-hypertensive Agents", "type": "DRUG" }, { "name": "Blinded fenofibrate or placebo plus simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "40 Years to 79 Years" }, "enrollment_count": 10251, "start_date": "1999-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 6, "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000620" }, { "nct_id": "NCT01281306", "title": "An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systolic Hypertension" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "AHU377", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 910, "start_date": "2011-01", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2016-01-29", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 19, "location_summary": "Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Belzoni", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281306" }, { "nct_id": "NCT00927394", "title": "Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Aliskiren", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "Placebo for Aliskiren", "type": "DRUG" }, { "name": "Placebo for Valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1143, "start_date": "2009-05", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2012-12-06", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 4, "location_summary": "Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Camden", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00927394" }, { "nct_id": "NCT04971720", "title": "PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Obesity", "Cardiovascular Diseases", "Hypertension", "Nocturnal Blood Pressure", "Natriuretic Peptides", "Renin-Angiotensin-Aldosterone System" ], "interventions": [ { "name": "Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet", "type": "DRUG" }, { "name": "Valsartan 80 mg Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2022-02-18", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971720" }, { "nct_id": "NCT04649229", "title": "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "LCZ 696", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Para-aminohippurate", "type": "DRUG" }, { "name": "Iohexol", "type": "DRUG" }, { "name": "Aprepitant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2021-05-27", "completion_date": "2025-05-22", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-25T12:22:05.075Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649229" } ] }